Posttransplant anemia: the role of sirolimus | Zendy

Steven Fishbane | Zendy; David J. Cohen | Zendy; Daniel W. Coyne | Zendy; Arjang Djamali | Zendy; Ajay Singh | Zendy; Jay B. Wish | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Posttransplant anemia: the role of sirolimus

Author(s) -

Steven Fishbane,

David J. Cohen,

Daniel W. Coyne,

Arjang Djamali,

Ajay Singh,

Jay B. Wish

Publication year - 2009

Publication title -

kidney international

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.499

H-Index - 276

eISSN - 1523-1755

pISSN - 0085-2538

DOI - 10.1038/ki.2009.231

Subject(s) - sirolimus , medicine , anemia , presentation (obstetrics) , intensive care medicine , renal function , surgery

Posttransplant anemia is a common problem that may hinder patients' quality of life. It occurs in 12 to 76% of patients, and is most common in the immediate posttransplant period. A variety of factors have been identified that increase the risk of posttransplant anemia, of which the level of renal function is most important. Sirolimus, a mammalian target of rapamycin inhibitor, has been implicated as playing a special role in posttransplant anemia. This review considers anemia associated with sirolimus, including its presentation, mechanisms, and management.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research